Risk Classification of Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin
The risk classification using CRP and hypercalcemia is useful for predicting the outcomes of patients with advanced UC treated with EV.
Authors
- Toshiyuki Unno
- Ayumi Uchiyama (ORCID: https://orcid.org/0000-0003-1594-7523)
- Keita Tamura (ORCID: https://orcid.org/0000-0002-4305-7328)
- Kyohei Watanabe (ORCID: https://orcid.org/0000-0002-8242-8611)
- YUTO MATSUSHITA
- Ryo Matsumoto (ORCID: https://orcid.org/0000-0001-7308-9120)
- Tomoko Mizuno (ORCID: https://orcid.org/0000-0001-8451-6909)
- Toshiki Ito (ORCID: https://orcid.org/0000-0002-2188-0516)
- Hiroshi Furuse
- Yohei Oishi
- Atsushi Otsuka (ORCID: https://orcid.org/0000-0001-6472-0988)
- Gaku Ishikawa
- Daisuke Motoyama (ORCID: https://orcid.org/0000-0002-5315-3874)
- Hiroki Tanaka (ORCID: https://orcid.org/0000-0002-6195-3177)
- Eiji Suzuki (ORCID: https://orcid.org/0000-0002-4980-964X)
- Shinya Watanabe (ORCID: https://orcid.org/0000-0001-8090-0428)
- Hiromitsu Watanabe (ORCID: https://orcid.org/0000-0001-5186-7139)
- Yuko Kitagawa (ORCID: https://orcid.org/0000-0002-0271-5670)
- Masao Nagata
- Shunsuke Watanabe (ORCID: https://orcid.org/0000-0001-7803-396X)
Institutions
- Hamamatsu University School of Medicine (JP)
- Seirei Mikatabara General Hospital (JP)
- Iwata City Hospital (JP)
- Fujieda Municipal General Hospital (JP)
- Hamamatsu Medical Center (JP)
Publication Details
- Journal
- Cancer Diagnosis & Prognosis
- Published
- 2024-11-02
- DOI
- https://doi.org/10.21873/cdp.10396
- Citations
- 2
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.15